MHRA Drug Safety Update September 2022
Links to the MHRA Drug Safety Update for September 2022 are listed below.
- Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations
- Rucaparib (Rubraca▼): withdrawal of third-line treatment indication
- COVID-19 vaccines and medicines: updates for September 2022
You can sign up to receive these alerts directly from the MHRA at: MHRA email alerts
Published 27/09/2022. Medicines Update blogs are correct at the time of publication.